{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:00:58Z","timestamp":1792155658953,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017723","name":"Innovent Biologics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.medj.2026.101132","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:16:33Z","timestamp":1777994193000},"page":"101132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Jiliang","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanmiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhai","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binkui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101132_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.medj.2026.101132_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101132_bib3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1200\/JCO.2016.68.2153","article-title":"CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study","volume":"35","author":"Qiu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101132_bib5","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/liv.15251","article-title":"Changing epidemiology of hepatocellular carcinoma in Asia","volume":"42","author":"Zhang","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.medj.2026.101132_bib6","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101132_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101132_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/gutjnl-2017-314138","article-title":"FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma","volume":"67","author":"Lyu","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.medj.2026.101132_bib9","doi-asserted-by":"crossref","first-page":"e057","DOI":"10.1097\/AS9.0000000000000057","article-title":"Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma","volume":"2","author":"Li","year":"2021","journal-title":"Ann. Surg. Open."},{"key":"10.1016\/j.medj.2026.101132_bib10","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.medj.2026.101132_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.medj.2026.101132_bib12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101132_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.24050","article-title":"Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?","volume":"115","author":"Forner","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.medj.2026.101132_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jhep.2017.03.007","article-title":"The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy","volume":"67","author":"Galle","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101132_bib15","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.bjc.6600185","article-title":"Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity","volume":"86","author":"Fischel","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2026.101132_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114501","article-title":"A matrix metalloproteinase-responsive hydrogel delivers dendritic cell-targeting nanoparticles for sustained antitumor immunity","volume":"390","author":"Wu","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.medj.2026.101132_bib17","article-title":"Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy","volume":"6","author":"Xing","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.medj.2026.101132_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101132_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101132_bib20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib21","volume":"34","author":"Maa\u00f1o","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102367","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","volume":"67","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.medj.2026.101132_bib23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4149\/neo_2023_230806N413","article-title":"Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial","volume":"70","author":"Liu","year":"2023","journal-title":"Neoplasma"},{"key":"10.1016\/j.medj.2026.101132_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.medj.2026.101132_bib25","article-title":"Sintilimab plus Lenvatinib conversion therapy for intermediate\/locally advanced hepatocellular carcinoma: A phase 2 study","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib26","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.medj.2026.101132_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/HEP.0000000000000776","article-title":"Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study","volume":"80","author":"Zhu","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101132_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000514313","article-title":"Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.medj.2026.101132_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapyversuslenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes","volume":"261","author":"D\u02bcAngelica","year":"2015","journal-title":"Ann. Surg."},{"key":"10.1016\/j.medj.2026.101132_bib31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/SLA.0000000000002511","article-title":"ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial)","volume":"267","author":"Sandstr\u00f6m","year":"2018","journal-title":"Ann. Surg."},{"key":"10.1016\/j.medj.2026.101132_bib32","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(25)00376-6","article-title":"Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study","volume":"26","author":"Shi","year":"2025","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000529574","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.medj.2026.101132_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1159\/000544981","article-title":"Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150","volume":"14","author":"Kudo","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.medj.2026.101132_bib35","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib36","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101132_bib37","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.medj.2026.101132_bib38","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/HEP.0000000000001233","article-title":"Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial","volume":"82","author":"Ma","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101132_bib39","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/SLA.0b013e3181b674df","article-title":"Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry","volume":"250","author":"Kishi","year":"2009","journal-title":"Ann. Surg."},{"key":"10.1016\/j.medj.2026.101132_bib40","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/bjs.5836","article-title":"Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome","volume":"94","author":"Ribero","year":"2007","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.medj.2026.101132_bib41","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1245\/s10434-012-2864-7","article-title":"Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases","volume":"20","author":"Shindoh","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib42","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00595-020-02088-2","article-title":"Issues to be considered to address the future liver remnant prior to major hepatectomy","volume":"51","author":"Kishi","year":"2021","journal-title":"Surg. Today"},{"key":"10.1016\/j.medj.2026.101132_bib43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archsurg.137.6.675","article-title":"Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization","volume":"137","author":"Abdalla","year":"2002","journal-title":"Arch. Surg."},{"key":"10.1016\/j.medj.2026.101132_bib44","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1245\/s10434-006-9045-5","article-title":"Improving resectability of hepatic colorectal metastases: expert consensus statement","volume":"13","author":"Abdalla","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.medj.2026.101132_bib45","first-page":"1117","article-title":"Expert consensus on pathological evaluation of efficacy after neoadjuvant and conversion therapy for hepatocellular carcinoma (2025 edition)","volume":"24","author":"Li","year":"2025","journal-title":"Chin J Dig Surg"},{"key":"10.1016\/j.medj.2026.101132_bib46","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.surg.2015.04.002","article-title":"Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study","volume":"158","author":"Qiu","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.medj.2026.101132_bib47","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/SLA.0000000000001339","article-title":"Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas","volume":"263","author":"Yang","year":"2016","journal-title":"Ann. Surg."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:09:15Z","timestamp":1783145355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666634026001352"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101132","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101132"}}